Moneycontrol PRO
HomeNewsBusinessCompaniesAbbott India posts 15% rise in Q2 profit on strong demand, price hikes

Abbott India posts 15% rise in Q2 profit on strong demand, price hikes

Abbott India continued to benefit from anti-infectives and medications for gastrointestinal conditions, the company said

November 07, 2024 / 15:19 IST
Abbott, which makes the antacid Digene, reported a profit of 3.59 billion rupees ($42.6 million) for the quarter ended Sept. 30, up nearly 15 percent from last year.
     
     
    26 Aug, 2025 12:21
    Volume
    Todays L/H
    More

    Drugmaker Abbott India reported a rise in second-quarter profit on November 7, helped by strong demand for its gastrointestinal and anti-infective medications.

    The company, which makes the antacid Digene, reported a profit of 3.59 billion rupees ($42.6 million) for the quarter ended Sept. 30, up nearly 15 percent from last year.

    Revenue from operations climbed 9.3 percent to 16.33 billion rupees.

    KEY CONTEXT

    Drugmakers such as Abbott India and rival GlaxoSmithKline Pharmaceuticals, who earn most of their revenue from India, have hiked prices of certain drugs not included in the Indian government's price-capped 'essential medicines list' to boost their earnings, analysts have said.

    Abbott India continued to benefit from anti-infectives and medications for gastrointestinal conditions, the company said in its latest annual report.

    Last week, rival GlaxoSmithKline Pharma reported higher second-quarter profit, boosted by demand for generic drugs and vaccines.

     

    Reuters
    first published: Nov 7, 2024 03:19 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347